A randomized, double blind, 2X2 factorial design study to evaluate the effects of telmisartan vs placebo, and of a low-glycemic diet vs control diet, in reducing intra-myocellular lipids in individuals with abdominal obesity.
Phase of Trial: Phase III
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Telmisartan (Primary)
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.
- 02 Feb 2010 Additional lead trial centres identified as reported by ClinicalTrials.gov.